News for hackers. Stuff that matters.
Re:Amygdala connectivity predicts ketamine treatment respons... by pgt on Monday November 28, 2022 @09:47AM (#33774227)
Most Ketamine users are unaware that even occasional usage can cause untreatable ulcerative cystitis, a.k.a. Ketamine Bladder Syndrome. Ketamine thins the urothelium while increasing the collagen to smooth muscle ratio and exacerbating interstitial fibrosis. The syndrome is untreatable and causes serious problems down the line.

One promising rat study from 2015 shows that EGCG (epigallocatechin gallate) extracted from green tea has a protective effect on the bladder, reversing ketamine-induced damage to control levels. If you are taking ketamine for major depression or recreationally, taking EGCG before may prevent long-term bladder damage.

Summary from the study:

> "Objective

To investigate the protective effect of green tea epigallocatechin gallate (EGCG) on long-term ketamine-induced ulcerative cystitis (KIC) using a ketamine addiction rat model.

Materials and methods

Thirty Sprague-Dawley rats were divided into three groups which received saline, ketamine (25 mg/kg/d), or ketamine combined with EGCG (10 μM/kg) for a period of 28 days. In each group, cystometry and a metabolic cage micturition pattern study were performed weekly. Masson's trichrome study was done to evaluate the morphologic changes. Western blot analyses were carried out to examine the expressions of inflammatory protein [transforming growth factor-β (TGF-β)] and fibrosis proteins (fibronectin and type I collagen) in bladder tissues.

Results

Chronic ketamine treatment resulted in bladder hyperactivity with a significant increase in micturition frequency and a decrease in bladder compliance. These alterations in micturition pattern were accompanied by increases in the expressions of inflammatory and fibrosis markers, TGF-β, fibronectin, and type I collagen after long-term ketamine treatment. Masson's trichrome stain showed that ketamine treatment decreased urothelium thickness while increasing the collagen to smooth muscle ratio and exacerbating interstitial fibrosis. By contrast, simultaneous EGCG and ketamine treatment reversed ketamine-induced damage to almost control levels, showing the protective effect of EGCG.

Conclusion

This protective effect of EGCG may come from its antiinflammatory and antifibrotic properties."

[^1]: https://www.sciencedirect.com/science/article/pii/S187952261...

Re:Amygdala connectivity predicts ketamine treatment respons... by chimeracoder on Monday November 28, 2022 @10:18AM (#33774639)
> even occasional usage can cause untreatable ulcerative cystitis, a.k.a. Ketamine Bladder Syndrome.

You'd have to stretch the definition of "occasional" to make this statement supportable. Clinical studies on the topic focus on chronic heavy users, whose usage far surpasses the dosing used by the median recreational user and typically persists for years. (In fact, most studies focus on recreational users who are using near-clinical levels, which is an order of magnitude more than the typical recreational dose, and doing so with regularity).

While it's possible that occasional use can cause issues, it's far from established fact, and the widespread usage of large doses of ketamine in inpatient settings for decades without reports of issues for those users would actually suggest otherwise.

Re:Amygdala connectivity predicts ketamine treatment respons... by mahathu on Monday November 28, 2022 @10:29AM (#33774780)
> (In fact, most studies focus on recreational users who are using near-clinical levels, which is an order of magnitude more than the typical recreational dose, and doing so with regularity).

Is that so? For ambien it's the opposite, usually the recreational dosage can be a lot higher for some users than a clinical dosage (5 or 10mg)

Re:Amygdala connectivity predicts ketamine treatment respons... by chimeracoder on Monday November 28, 2022 @10:39AM (#33774912)
> Is that so? For ambien it's the opposite, usually the recreational dosage can be a lot higher for some users than a clinical dosage (5 or 10mg)

Correct. What you are saying is true for almost all drugs: recreational doses are typically higher than clinical doses. Ketamine is the exception.

The recreational dose for a ketamine-naive user[0] is somewhere between 5-20mg. The clinical dose for depression is 86mg (not a typo), which is sometimes doubled, and the clinical dose for anesthetic purposes (which is what ketamine is mostly used for) is between 500mg-1g. The latter is IM injection, so it's also much more bioavailable than the first two (ie, the effective dose differential is even higher).

Of course, regular users develop a tolerance and heavy chronic users of ketamine can do more. But that's due to tolerance, not representative of the typical baseline recreational dose. (If they were to need ketamine for inpatient anesthetia, they would need absolutely massive doses for it to be effective).

[0] "naive" is not a judgmental term; it's the clinical term used to describe a user who has no prior experience with the drug, or who has no baseline tolerance (ie, whose prior usage is far enough in the past that it is no longer relevant).

Re:Amygdala connectivity predicts ketamine treatment respons... by csnover on Monday November 28, 2022 @12:18PM (#33776341)
> Correct. What you are saying is true for almost all drugs: recreational doses are typically higher than clinical doses. Ketamine is the exception.

To clarify: my understanding is that ketamine acts as a dissociative hallucinogen at lower doses and an anaesthetic at higher doses, so taking a higher dose will just knock someone out instead of giving them the dissociative/hallucinogenic effects.

> The clinical dose for depression is 86mg (not a typo), which is sometimes doubled, and the clinical dose for anesthetic purposes (which is what ketamine is mostly used for) is between 500mg-1g. The latter is IM injection, so it's also much more bioavailable than the first two (ie, the effective dose differential is even higher).

Ketamine is normally dosed based on body weight[0]. For depression IV, the dose is 0.1–0.75mg/kg/40mins, most commonly 0.5mg/kg/40mins. Clinical use in IM seems to be less consistent, with some clinicians using the same range and others doubling it, so the 86mg could be used for a wide range of body weights.

[0] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023575/table/T...

[1] https://www.psychiatrist.com/jcp/depression/ketamine-for-dep...

Re:Amygdala connectivity predicts ketamine treatment respons... by chimeracoder on Monday November 28, 2022 @01:56PM (#33777887)
> Ketamine is normally dosed based on body weight[0]. For depression IV, the dose is 0.1–0.75mg/kg/40mins, most commonly 0.5mg/kg/40mins

If we're being specific, the FDA-approved treatment of ketamine for depression is a fixed 84mg dose. It is not adjusted for body weight.

(I did invite irony by saying that it wasn't a typo - it's 84 and 56 for redoing, not 86 and 54).

Re:Amygdala connectivity predicts ketamine treatment respons... by csnover on Tuesday November 29, 2022 @11:28PM (#33797033)
Thanks for the clarification! Since you’d mentioned IM administration it didn’t cross my mind that you were talking about Spravato. That typo is regrettable, but unimportant to your point that the nasal spray does indeed use two fixed doses.
Re:Amygdala connectivity predicts ketamine treatment respons... by cmrdporcupine on Monday November 28, 2022 @10:47AM (#33775013)
Thanks for bringing this up. It's super important. And also makes me why other drugs in this class (dissociatives) aren't being looked more aggressively. Dextromethorphan -- in common cough syrup -- is one example. It has other side effects (nausea, etc.) but doesn't have the bladder destructive issues associated with ketamine.
Re:Amygdala connectivity predicts ketamine treatment respons... by chimeracoder on Monday November 28, 2022 @10:55AM (#33775154)
> Thanks for bringing this up. It's super important. And also makes me why other drugs in this class (dissociatives) aren't being looked more aggressively. Dextromethorphan -- in common cough syrup -- is one example. It has other side effects (nausea, etc.) but doesn't have the bladder destructive issues associated with ketamine

The fact that they're both dissociatives doesn't mean they're substitutable in any given context.

Dextromethorphan is a much riskier drug overall than ketamine, in almost every measurable way. It's very easy to overdose on dextromethorphan, to the point where people routinely do it by accident while self-medicating for a cough. By contrast, it's actually quite difficult to overdose on ketamine - the LD50 is quite high, and a person would likely incapacitate themselves halfway through and be unable to finish.

They also have dramatically different effects - there are actually very few contexts in which both could be considered an acceptable choice for a given goal.

The bladder issues with ketamine are only documented for chronic heavy users. There's no clinical evidence of it for one-time use, and given the extensive use of ketamine in controlled settings for several decades, the absence of evidence is (in this case) strong evidence of absence.

Re:Amygdala connectivity predicts ketamine treatment respons... by cmrdporcupine on Monday November 28, 2022 @11:32AM (#33775697)
Honestly, I'm speaking from personal experience with both drugs. When you're talking about overdose on dextromethorphan I think you're mischaracterizing. The LD50 of dextromethorpan is 150mg/kg in mice. A dissociative/psychedelic dose of dextromethorpan is 300-500mg in an average adult. A typical cough medicine is 15-30mg per dose, and a bottle usually has no more than 250mg or 300mg. Nobody is "accidentally" hitting a toxic dose. Overdosing really means: getting somewhat similar effects to ketamine -- along with a nasty dose of dizziness and nausea. To have an extremely serious reaction to dextromethorphan that is drastic, you'd have to consume multiple bottles of cough syrup.

On other hand I've been in, and had friends in, so-called "k-holes" because of doses of ketamine that were too high and the experience was ... awful. Imagine thinking you're dead, but you're still conscious.

Both are NMDA antagonists. Both provide emotional and physical dissociation. They are in the a similar class of experiences.

Psychotherapeutic doses of ketamine are not one-time. At least not from the reading I've been doing. They have been found to be more effective done over several sessions. I honestly worry about the potential for bladder damage because it has not been studied well and also this kind of treatment is something we're looking into for a loved one

Re:Amygdala connectivity predicts ketamine treatment respons... by curioussavage on Monday November 28, 2022 @12:24PM (#33776424)
Auvelity, a drug that combines dextromethorphan and bupropion (included to keep the dextromethorphan in the system longer) was just made available this quarter.
Re:Amygdala connectivity predicts ketamine treatment respons... by cmrdporcupine on Monday November 28, 2022 @07:01PM (#33781713)
I kind of .. DIY'd this combination myself for a bit.

It allows you to take a much lower dose of dextromethorphan and so have fewer undesirable side effects. It helped me cope with some chronic physical pain I was suffering with at the time (in addition to depression).

Re:Amygdala connectivity predicts ketamine treatment respons... by cmrdporcupine on Monday November 28, 2022 @07:07PM (#33781762)
"Although Axsome has not yet announced a price, it’s anticipated that it will be a relatively expensive product compared with generic SSRIs and SNRIs, which are very well-established on the MDD market. With a comparatively high expected price, Auvelity may see its use restricted by payers to second and later lines of therapy."

This is insane gouging, as you could literally make it yourself by getting a prescription for generic bupoprion and some store-bought cough medicine.